Efficacy of pregabalin in the treatment of generalized anxiety disorder: Double-blind, placebo-controlled comparison of BID versus TID dosing

Journal of Clinical Psychopharmacology

Volumn 25, Issue 2, 2005, Pages 151-158

  Pohl, Robert B ^a,d   Feltner, Douglas E ^b   Fieve, Ronald R ^c   Pande, Atul C ^b  

^a University Psychiatric Centers   (United States)

^b PFIZER INC   (United States)

^c Fieve Clinical Services   (United States)

^d UPC Jefferson   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIOLYTIC AGENT; PLACEBO; PREGABALIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EUPHORIA; FEMALE; FLATULENCE; GENERALIZED ANXIETY DISORDER; HAMILTON SCALE; HUMAN; INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; STATISTICAL SIGNIFICANCE; THOUGHT DISORDER; TRANQUILIZING ACTIVITY; VISUAL IMPAIRMENT; XEROSTOMIA;

ADULT; ANXIETY DISORDERS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED;

EID: 15444363963     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000155820.74832.b0     Document Type: Article

References (49)

1. Brawman-Mintzer O. Pharmacologic treatment of generalized anxiety disorder. Psychiatr Clin North Am. 2001;24:119-137.
2. Lader M. Assessing the potential for buspirone dependence or abuse and effects of its withdrawal. Am J Med. 1987;82:20-26.
3. Goa KL, Ward A. Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs. 1986;32:114-129.
4. Rickels K, Schweizer E, Csanalosi I, et al. Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry. 1988;45:444-450.
5. Cohn JB, Bowden CL, Fisher JG, et al. Double-blind comparison of buspirone and clorazepate in anxious outpatients. Am J Med. 1986;80:10-16.
6. Gorman JM. Treatment of generalized anxiety disorder. J Clin Psychiatry. 2002;63(suppl 8):17-23.
7. Davidson JR, DuPont RL, Hedges D, et al. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry. 1999;60:528-535.
8. Rickels K, Pollack MH, Sheehan DV, et al. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry. 2000;157:968-974.
9. Gelenberg AJ, Lydiard RB, Rudolph RL, et al. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA. 2000;283:3082-3088.
10. Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry. 2001;179:15-22.
11. Pollack MH, Zaninelli R, Goddard A, et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001;62:350-357.
12. Liebowitz MR, Stein MB, Tancer M, et al. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry. 2002;63:66-74.
13. Allgulander C, Dahl AA, Austin C, et al. Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry. 2004;161:1642-1649.
14. Culpepper L. Generalized and psychic anxiety symptoms: cross-disorder prevalence and responsivity to sertraline treatment. Poster presented at: Annual Meeting of the Anxiety Disorders Association of America; March 2003; Toronto, Canada.
15. Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003;60:1274-1283.
16. Rosenstock J, Tuchman M, LaMoreaux L, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004;110:628-638.
17. Arroyo S, Anhut H, Kugler AR, et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled dose-response study in adults with partial seizures. Epilepsia. 2004;45:20-27.
18. French JA, Kugler AR, Robbins JL, et al. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology. 2003;60:1631-1637.
19. Feltner DE, Crockatt JG, Dubovsky SJ, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2003;23:240-249.
20. Pande AC, Crockatt JG, Feltner DE, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry. 2003;160:533-540.
21. Busch JA, Strand JA, Posvar EL, et al. Pregabalin single-dose pharmacokinetics and safety/tolerance in healthy subjects after oral administration of pregabalin solution or capsule doses [abstract]. Epilepsia. 1998;39(Suppl 6):58.
22. +-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett. 2000;280:107-110.
23. Maneuf YP, McKnight AT. Block by gabapentin of the facilitation of glutamate release from rat trigeminal nucleus following activation of protein kinase C or adenylyl cyclase. Br J Pharmacol. 2001;134:237-240.
24. 3H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther. 2000;295:1086-1093.
25. Field MJ, Oles RJ, Singh L. Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity. Br J Pharmacol. 2001;132:1-4.
26. 2-delta subunit of a calcium channel. J Biol Chem. 1996;271(10):5768-5776.
27. Bryans JS, Wustrow DJ. 3-Substituted GABA analogs with central nervous system activity: a review. Med Res Rev. 1999;16:519-526.
28. 3H]-norepinephrine release from rat neocortical slices. Synapse. 2002;45:171-190.
29. 2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology. 2002;42:229-236.
30. Hindmarch I, Dawson J, Stanley N. Evaluation of cognitive and psychomotor profile of pregabalin compared to alprazolam in normal volunteers. Poster presented at: APA Annual Meeting; May 2002; Philadelphia.
31. Borbely AA, Akerstedt T, Benoit O, et al. Hypnotics and sleep physiology: a consensus report. European Sleep Research Society, Committee on Hypnotics and Sleep Physiology. Eur Arch Psychiatry Clin Neurosci. 1991;241:13-21.
32. Yyldyz A, Sachs GS. Administration of antidepressants. Single versus split dosing: a meta-analysis. J Affect Disord. 2001;66:199-206.
33. Dunbar GC, Sheehan MF, Sheehan DV, et al. The validity of the Mini International Neuropsychiatrie Interview (MINI) according to the SCID P and its reliability. Eur Psychiatr. 1997;12:232-241.
34. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychiatry. 1959;32:10.
35. Lipman RS, Covi L. Outpatient treatment of neurotic depression: medication and group psychotherapy. In: Spitzer R, Klein D, eds. Evaluation of Psychological Therapies. Baltimore, MD: Johns Hopkins University Press; 1976:178-218.
36. Raskin A, Schulterbrandt J, Reatig N, et al. Replication of factors of psychopathology in interview, ward behaviour and self report ratings of hospitalized depressives. J Nerv Ment Dis. 1969;148:87-98.
37. Hamilton MA. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
38. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: National Institute of Mental Health, US Dept of Health, Education, and Welfare; 1976:76-338.
39. COSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms. 4th ed. Department of Health and Human Services, FDA; 1996.
40. Rickels K, Schweizer E, Case WG, et al. Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatry. 1990;47:899-907.
41. SAS/Stat User's Guide. Volumes 1 and 2, version 6.0. Cary, NC: SAS Institute; 1989.
42. Neter J, Wasserman W, Kutner MH. Applied Linear Statistical Models. Boston, Mass: Irwin; 1990:861-898.
43. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988:800-802.
44. Hosmer DW, Lemeshow L. Applied Logistic Regression. New York, NY: John Wiley and Sons; 1989.
45. Stokes ME, Davis CS, Koch GG. Categorical Data Analysis Using the SAS® System. Cary, NC: SAS Institute Inc; 1995.
46. Pourmotabbed T, McLeod DR, Hoehn-Saric R, et al. Treatment, discontinuation, and psychomotor effects of diazepam in women with generalized anxiety disorder. J Clin Psychopharmacol. June 1996;16(3):202-207.
47. Rickels K, Downing R, Schweizer E, et al. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry. November 1993;50(11):884-895.
48. Meoni P, Salinas E, Brault Y, et al. Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder. J Clin Psychiatry. 2001;62:888-893.
49. Cole JO, Kando JC. Adverse behavioral events reported in patients taking alprazolam and other benzodiazepines. J Clin Psychiatry. 1993;54(suppl):49-61.